Osteoporosis Drug Blocks Spinal Damage in Animal Study, Researchers Say
- Researchers found that a bisphosphonate medication commonly used to treat osteoporosis blocked abnormal mineral buildup in the spines of genetically altered zebrafish.
- The study revealed that structural tissue breakdown in the spine begins before mineral deposits and spinal fusions become visible.
- While the findings raise hopes for chronic back pain treatments, the drug’s effects have not yet been confirmed in human clinical trials.
Most people experience back pain at some point in their lives, often driven by the gradual deterioration of intervertebral discs that cushion the bones of the spine. As these discs wear down, they contribute to pain, stiffness, and reduced mobility.
Despite the widespread impact of this condition, no medications are currently available that can stop or reverse the degenerative process, leaving surgery as the only established long-term intervention for severe cases. Scientists at the Universities of Edinburgh and Bristol turned to zebrafish to investigate the underlying genetic and biological causes of this spinal deterioration, as ScienceDaily reported.
Zebrafish Lacking Collagen IX Gene Develop Spinal Mineralization and Fusion
Researchers studied zebrafish that had been bred without a functioning copy of a gene associated with collagen IX, a protein that helps maintain the structural integrity of spinal discs. As the fish aged, abnormal mineral deposits accumulated in the tissues separating their vertebrae, a process known as mineralization.
This buildup caused normally flexible structures to become rigid, alongside spinal fusion where neighboring vertebrae joined together. Scientists discovered that an underlying supportive layer began to break down well before the mineral deposits appeared.
To understand the molecular drivers behind this degeneration, the team examined gene activity in the zebrafish. They detected disturbances in fat metabolism, the mTOR signaling system, phosphate regulation, and vitamin A signaling. These findings indicate that spinal disc degeneration involves complex alterations in how cells process nutrients and handle minerals, moving beyond simple mechanical wear and tear.
Bisphosphonates Prevent Mineral Buildup
Testing potential ways to reduce these abnormalities, researchers discovered that a medication belonging to the bisphosphonate class successfully blocked abnormal mineral buildup in the zebrafish spines. Bisphosphonates are widely prescribed to treat osteoporosis by protecting bones and slowing tissue breakdown. Limiting food consumption and administering medications that suppressed fat metabolism also reduced spinal fusions in the experimental models.
Dr. Erika Kague, who led the research at the University of Edinburgh’s Institute of Genetics and Cancer, stated “For decades, surgery has been the only real answer for disc disease. By understanding the biology that drives the spine to harden, our zebrafish studies point to several ways of slowing it down, including a drug already used safely in patients.” The study was published in the journal Communications Biology and received financial backing from Arthritis UK and BBSRC.
Experts Welcome Zebrafish Findings but Confirm Human Studies Still Needed
Dr. Caroline Aylott, Head of Research Delivery at Arthritis UK, noted the broader context for patients, stating “For the 9.5 million people across the UK living with back pain this research brings fresh hope that potential new therapeutic approaches are on the horizon.” Dr. Jef Grainger, Executive Director for Bioscience Advancing Knowledge at BBSRC, added that the study highlights how publicly funded discovery bioscience generates essential knowledge for major health challenges.
Despite these promising results in animal models, the findings remain unconfirmed in humans. Researchers emphasize that further investigations are required to determine whether the same biological mechanisms operate in people and whether targeted therapies can safely prevent or slow spinal disc degeneration before clinical application can be considered.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.